VC
PASG icon

Vivo Capital’s Passage Bio PASG Stock Holding History

Vivo Capital’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-26,963
Closed -$5.37M – 61
2021
Q3 		$5.37M Sell
26,963
-5,337
-17% -$1.27M 0.24% 50
2021
Q2 		$8.55M Sell
32,300
-38,375
-54% -$11.9M 0.37% 46
2021
Q1 		$24.7M Sell
70,675
-3,677
-5% -$1.57M 0.87% 25
2020
Q4 		$38M Sell
74,352
-35,221
-32% -$14.1M 1.7% 13
2020
Q3 		$28.7M Sell
109,573
-1,906
-2% -$656K 1.66% 15
2020
Q2 		$60.9M Hold
111,479
– – 4.37% 5
2020
Q1 		$35.1M Buy
+111,479
New +$34.9M 3.18% 9

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital's PASG Position: Q4 2021 in Review

Vivo Capital sold out of Passage Bio (PASG) in Q4 2021, closing a stake of 26,963 shares — an estimated $5.37M sold.

Vivo Capital first reported a position in PASG in Q1 2020 and held it in 7 quarters. The position peaked at $60.9M in Q2 2020. 99 funds tracked by Wall St. Rank hold PASG as of Q4 2021.

  • Vivo Capital reported no remaining Passage Bio position as of Q4 2021 after selling out during the quarter.
  • Vivo Capital sold 26,963 Passage Bio shares in Q4 2021, an estimated $5.37M.
  • Vivo Capital first reported a position in Passage Bio in Q1 2020 and held it in 7 quarters.
  • Vivo Capital's Passage Bio position peaked at $60.9M in Q2 2020.
  • 99 funds tracked by Wall St. Rank held Passage Bio as of Q4 2021.

Based on Vivo Capital's 13F filing for Q4 2021, filed 11 Feb 2022.